Compare J M Smucker Co (SJM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs BIO-TECHNE Corp — how do they compare? J M Smucker Co trades at $120.56 (market cap $12.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: J M Smucker Co and BIO-TECHNE Corp are close in size by market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and BIO-TECHNE Corp for 63 Days on average.
| SJM | TECH | |
|---|---|---|
Market Cap | $12.76B | $11.36B |
Volume | 1,300,545 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $72.61 |
52-Week Low | $89.53 | $43.31 |
Typical Hold Time | 74 Days | 63 Days |
Enterprise Value | $19.61B | $11.39B |
Dividend Yield | 3.75% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though recent quarters have beaten EPS estimates. Analyst consensus is a Buy with a $137.29 price target, and a dividend of $1.12 is scheduled for September 2026.
The outlook is mixed: strong recent earnings beats and positive analyst sentiment suggest upside, but high P/E of 54.17 and volatile profitability pose risks. Key opportunities include raised FY2027 guidance and brand strength, while risks involve margin pressure and high debt levels impacting shareholder value.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
